AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
But now it must show that varseta-M can move into a registrational trial.
New data with pasritamig plus docetaxel support a recent pivotal start.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The month saw the first commissioner's priority voucher approval in oncology.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
